WRN
54 programs · 54 companies
Programs
54
Companies
54
Active Trials
31
Targeting WRN
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | CKDPSP | |
| Zorisotorasib | AstraZeneca | Phase 1 | PAHT2D | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | SMACF | |
| Lisorapivir | Takeda | Preclinical | MCC | |
| Nirafutibatinib | Bayer | Phase 2 | ThymomaSMA | |
| TSH-7567 | Taysha Gene | Phase 1/2 | BCCMCL | |
| BLU-5648 | Bluebird Bio | Approved | PTSD | |
| CSL-4826 | CSL Limited | NDA/BLA | RCCParkinson's | |
| Sotosacituzumab | Sun Pharma | Approved | Breast Ca | |
| MEM-IIT-110 | Memorial Sloan Kettering | Phase 1/2 | ADHD | |
| MD-IIT-494 | MD Anderson | Phase 1 | RCC | |
| NCI-IIT-608 | NCI | NDA/BLA | Pompe | |
| SWO-IIT-827 | SWOG | Phase 2/3 | DLBCL | |
| SEO-IIT-337 | Seoul Natl Univ Hosp | Phase 1/2 | Pompe | |
| UCS-IIT-728 | UCSF | Phase 2 | T2D | |
| IMM-7074 | ImmunoGen (AbbVie) | Phase 1/2 | ALLDravet | |
| ABL-5779 | Ablynx (Sanofi) | Phase 1/2 | ADHD | |
| INS-408 | Insilico Medicine | Phase 1 | GISTLGS | |
| Sotoderotide | Abeona | Phase 3 | Alzheimer's | |
| DEE-8943 | Deerfield Mgmt | Phase 2/3 | CML | |
| CN-9071 | CN Bio Innovations | Preclinical | MelanomaSchizophrenia | |
| Nidatinib | Palatin Technologies | Phase 2 | Atopic DermRB | |
| XBI-1781 | XBiotech | Phase 3 | SCLCADPKD | |
| Sovasotorasib | Aadi Biosciences | NDA/BLA | RSV | |
| ARA-160 | Aravive | Phase 1 | CeliacSCLC | |
| Elrasotorasib | AN2 Therapeutics | NDA/BLA | Ovarian CaMigraine | |
| Kemarelsin | Livzon Pharma | Phase 1/2 | Huntington's | |
| Olpasotorasib | Celltrion | Phase 1/2 | Breast CaHCC | |
| Zoribrutinib | Eutilex | Phase 2/3 | Huntington'sUrothelial Ca | |
| NOR-1166 | NorthStar Med | Phase 1 | NSCLCNB | |
| Teranesiran | Affinia | Phase 1 | BCCHuntington's | |
| BIG-3814 | BigHat Bio | Approved | Hemophilia A | |
| ALK-4522 | Alkermes | Phase 1 | HS | |
| DUK-IIT-613 | Duke Cancer | Approved | Psoriasis | |
| Ivonaritide | Applied DNA | Phase 2/3 | DravetSCLC | |
| SAN-4302 | Sana Biotech | Phase 1 | Alzheimer'sPBC | |
| 456-9934 | AnGes | Phase 1/2 | Crohn'sBladder Ca | |
| 458-3114 | Chiome Bio | Phase 1/2 | Celiac | |
| MRK-7986 | Merck KGaA | Phase 1/2 | Ewing SarcomaADPKD | |
| Kematinib | Fennec Pharma | Phase 3 | FTDRSV | |
| Rimasotorasib | Photocure | Phase 1/2 | ASMelanoma | |
| BSL-7024 | Basilea Pharma | Phase 1 | SCD | |
| Pemiinavolisib | Stallergenes Greer | Phase 1/2 | Prostate CaMG | |
| Mirivorutinib | Tessa Therapeutics | Phase 2/3 | SLEET | |
| Zoriinavolisib | MiNA Therapeutics | Phase 2/3 | MyelofibrosisPsA | |
| Rimabrutinib | TaiGen Biotherapeutics | Approved | Parkinson'sLGS | |
| Rimazanubrutinib | Ache Laboratorios | NDA/BLA | CSU | |
| CHA-IIT-311 | Charité Berlin | Phase 2 | CML | |
| PET-IIT-224 | Peter MacCallum | Preclinical | Gastric Ca | |
| Ribotapinarof | Kelun Pharma | Phase 2 | FSGS | |
| Gozefutibatinib | Sorriso Pharma | NDA/BLA | RASCD | |
| Zoricapivasertib | Humanwell Healthcare | Phase 1 | GBMUrothelial Ca | |
| Gelibrutinib | IDEXX Laboratories | NDA/BLA | Endometrial Ca | |
| YB-6541 | Y Biologics | Phase 3 | HNSCC |